Catalyst Funds Management Pty Ltd Boosts Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Catalyst Funds Management Pty Ltd boosted its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 60.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,250 shares of the biopharmaceutical company's stock after buying an additional 4,250 shares during the period. Catalyst Funds Management Pty Ltd's holdings in Insmed were worth $777,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Picton Mahoney Asset Management grew its stake in Insmed by 7.4% during the fourth quarter. Picton Mahoney Asset Management now owns 48,897 shares of the biopharmaceutical company's stock worth $3,374,000 after buying an additional 3,354 shares in the last quarter. Swiss National Bank grew its stake in Insmed by 6.1% during the fourth quarter. Swiss National Bank now owns 321,100 shares of the biopharmaceutical company's stock worth $22,169,000 after buying an additional 18,600 shares in the last quarter. Avantax Advisory Services Inc. boosted its stake in shares of Insmed by 19.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 8,967 shares of the biopharmaceutical company's stock valued at $619,000 after purchasing an additional 1,486 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Insmed by 18.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,476 shares of the biopharmaceutical company's stock valued at $3,002,000 after purchasing an additional 6,755 shares in the last quarter. Finally, Edgestream Partners L.P. boosted its stake in shares of Insmed by 1,242.1% in the 4th quarter. Edgestream Partners L.P. now owns 43,619 shares of the biopharmaceutical company's stock valued at $3,011,000 after purchasing an additional 40,369 shares in the last quarter.

Remove Ads

Insmed Trading Up 2.5 %

Shares of NASDAQ:INSM traded up $1.95 during mid-day trading on Wednesday, hitting $78.94. The company had a trading volume of 1,137,784 shares, compared to its average volume of 2,169,416. The firm has a fifty day moving average price of $76.61 and a 200 day moving average price of $73.70. The company has a market capitalization of $14.29 billion, a PE ratio of -14.12 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

INSM has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Stifel Nicolaus reduced their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. UBS Group raised their price target on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $93.33.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the sale, the insider now owns 102,766 shares of the company's stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the transaction, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.